


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
ENTERED INTO EXCLUSIVE PROMOTION AGREEMENT

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharm**”) announces that Chia-Tai Tianqing Pharmaceutical Group Co., Ltd. (“**Chia-Tai Tianqing**”), a subsidiary of the Company, entered into an exclusive promotion agreement with Ping An-Shionogi Co., Ltd. (“**Ping An-Shionogi**”), pursuant to which Chia-Tai Tianqing is granted exclusive promotion rights for Ensitrelvir, a treatment for new coronavirus infection (“**COVID-19**”), in Mainland China for an initial period of five years.

Ensitrelvir is a novel oral drug for the treatment of COVID-19. Clinical trial results have shown that the drug has demonstrated significant improvement and antiviral efficacy against the five major symptoms of COVID-19 typical of the Omicron strain and has a good safety profile. Ping An-Shionogi has submitted the relevant preparation materials for new drug application of Ensitrelvir to the Center for Drug Evaluation of the National Medical Products Administration of China. Ping An-Shionogi’s parent company, Shionogi & Co., Ltd., has obtained a manufacturing and marketing license for Ensitrelvir in Japan in November 2022, covering patients aged 12 years and above. Through this cooperation, Chia-Tai Tianqing of Sino Biopharm has become the exclusive marketing promotion partner for Ensitrelvir in China, which will help fight the COVID-19 epidemic by providing early access to Ensitrelvir by patients in China.

About Ensitrelvir

Ensitrelvir is a novel 3CL protease inhibitor, jointly developed by Hokkaido University and Shionogi & Co., Ltd. 3CL protease is an enzyme essential for the replication of the novel coronavirus (SARS-CoV-2), and Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease.

As shown in the results of the Phase IIb study of Ensitrelvir published by Shionogi, the investigators evaluated the proportion of patients with positive viral titres in each group: the proportion of patients with positive viral titres on day 4 decreased by 98.1% in the low-dose group and 94.6% in the high-dose group compared to the placebo group, both achieving significant differences. The time required for a positive titre to turn negative was reduced by 40 hours in the low-dose group and 30 hours in the high-dose group compared to the placebo group, demonstrating rapid clearance of the virus. In the follow-up phase III clinical study, Ensitrelvir showed significant improvement in the five major symptoms of COVID-19 (i.e. nasal congestion/runny nose, sore throat, cough, fever and fatigue) typical of the Omicron strain in 1,821 enrolled patients with mild to moderate symptoms (regardless of risk of severe disease or vaccination status), with a time to resolution of symptoms (167.9 hours vs. 192.2 hours, $p=0.04$) reached the primary endpoint, while as a secondary endpoint, the time for viral titre transition was significantly better than placebo. In terms of safety, no serious adverse events or side effects were observed in the Phase II and Phase III clinical studies. As Ensitrelvir does not require the use of other drugs as a booster, the risk of drug interactions is reduced and compliance is better in elderly patients with possible co-morbidities.

A global phase III clinical study of Ensitrelvir on non-hospitalised patients with SARS-CoV-2 infection (SCORPIO-HR study) is ongoing worldwide. In addition, a global phase III clinical study (STRIVE study) on hospitalised patients with SARS-CoV-2 infection is scheduled to commence in the near future, and studies on onset prevention for household members living with infected patients and on children under 12 years of age are also in preparation.

About Ping An-Shionogi

Established in China in 2020, Ping An-Shionogi is committed to improving the health and quality of life of the Chinese people by providing a wide range of healthcare solutions, including new drugs, new healthcare services and high-quality generic drugs developed by its Japanese parent company, Shionogi & Co., Ltd.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 29 December 2022

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.